The glycocalyx—linking albuminuria with renal and cardiovascular disease
- 13 October 2015
- journal article
- review article
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 11 (11), 667-676
- https://doi.org/10.1038/nrneph.2015.162
Abstract
Albuminuria is commonly used as a marker of kidney disease progression, but some evidence suggests that albuminuria also contributes to disease progression by inducing renal injury in specific disease conditions. Studies have confirmed that in patients with cardiovascular risk factors, such as diabetes and hypertension, endothelial damage drives progression of kidney disease and cardiovascular disease. A key mechanism that contributes to this process is the loss of the glycocalyx--a polysaccharide gel that lines the luminal endothelial surface and that normally acts as a barrier against albumin filtration. Degradation of the glycocalyx in response to endothelial activation can lead to albuminuria and subsequent renal and vascular inflammation, thus providing a pathophysiological framework for the clinical association of albuminuria with renal and cardiovascular disease progression. In this Review, we examine the likely mechanisms by which glycocalyx dysfunction contributes to kidney injury and explains the link between cardiovascular disease and albuminuria. Evidence suggests that glycocalyx dysfunction is reversible, suggesting that these mechanisms could be considered as therapeutic targets to prevent the progression of renal and cardiovascular disease. This possibility enables the use of existing drugs in new ways, provides an opportunity to develop novel therapies, and indicates that albuminuria should be reconsidered as an end point in clinical trials.Keywords
This publication has 106 references indexed in Scilit:
- Glomerular Endothelial Cell Injury and Damage Precedes That of Podocytes in Adriamycin-Induced NephropathyPLOS ONE, 2013
- Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic NephropathyJournal of the American Society of Nephrology, 2012
- Heparanase Is Essential for the Development of Diabetic Nephropathy in MiceDiabetes, 2011
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitusDiabetologia, 2010
- Paradoxical glomerular filtration of carbon nanotubesProceedings of the National Academy of Sciences, 2010
- Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment TargetsCurrent Hypertension Reports, 2010
- CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density LipoproteinThe American Journal of Pathology, 2009
- Deficiency of Endothelial Nitric-Oxide Synthase Confers Susceptibility to Diabetic Nephropathy in Nephropathy-Resistant Inbred MiceThe American Journal of Pathology, 2007
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005